文献速递乳腺癌

适应性旁路MEK抑制过程中的增强子重塑可被P-TEFb复合物药理靶向减弱

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
PubMed 文献 · Cancer Discov · 2017-01-20

在 triple-negative breast cancer(TNBC)患者中,trametinib 抑制 MEK1/2 后肿瘤样本出现显著转录反应,包括 receptor tyrosine kinases(RTK)上调。临床前模型中,MEK 抑制诱导全基因组增强子形成,涉及 BRD4、MED1、H3K27 乙酰化及 p300 的募集;抑制 P-TEFb 相关蛋白 BRD4 和 CBP/p300 可阻止增强子播种和 RTK 上调,BRD4 bromodomain 抑制剂克服 trametinib 耐药并在细胞、异种移植及同基因小鼠 TNBC 模型中产生持续生长抑制。

要点

  • TNBC 患者 trametinib 治疗一周前后肿瘤样本显示显著转录反应,包括 RTK 上调。
  • 临床前模型中 MEK 抑制诱导全基因组增强子形成,涉及 BRD4、MED1、H3K27 乙酰化及 p300。
  • BRD4 bromodomain 抑制剂克服 trametinib 耐药,在细胞、异种移植及同基因小鼠 TNBC 模型中持续抑制生长。

核心结论

  • 在 TNBC 患者肿瘤中观察到对药理 MEK 抑制的广泛转录适应;临床前模型中,MEK 抑制诱导全基因组染色质显著改变,表现为从头增强子形成和增强子重塑;药理靶向增强子处的 P-TEFb 复合物成员是持久抑制此类适应的有效策略。

研究设计与样本

  • TNBC 患者接受 trametinib 治疗一周前后采集肿瘤样本进行转录分析;临床前模型包括细胞、异种移植及同基因小鼠 TNBC 模型。

主要发现

  • TNBC 患者 trametinib 治疗一周前后肿瘤样本显示显著转录反应,包括 RTK 上调。
  • 临床前模型中,MEK 抑制诱导全基因组增强子形成,涉及 BRD4、MED1、H3K27 乙酰化及 p300 的播种,驱动转录适应。
  • 抑制 P-TEFb 相关蛋白 BRD4 和 CBP/p300 可阻止增强子播种和 RTK 上调。
  • BRD4 bromodomain 抑制剂克服 trametinib 耐药,在细胞、异种移植及同基因小鼠 TNBC 模型中产生持续生长抑制。

临床怎么用

  • 作者指出,药理靶向 P-TEFb 复合物成员联合 trametinib 抑制 MEK 是持久抑制适应性耐药所需表观基因组重塑的有效策略;原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting the dysregulated BRAF-MEK-ERK pathway in cancer has increasingly emerged in clinical trial design. Despite clinical responses in specific cancers using inhibitors targeting BRAF and MEK, resistance develops often involving nongenomic adaptive bypass mechanisms. Inhibition of MEK1/2 by trametinib in patients with triple-negative breast cancer (TNBC) induced dramatic transcriptional responses, including upregulation of receptor tyrosine kinases (RTK) comparing tumor samples before and after one week of treatment. In preclinical models, MEK inhibition induced genome-wide enhancer formation involving the seeding of BRD4, MED1, H3K27 acetylation, and p300 that drives transcriptional adaptation. Inhibition of the P-TEFb-associated proteins BRD4 and CBP/p300 arrested enhancer seeding and RTK upregulation. BRD4 bromodomain inhibitors overcame trametinib resistance, producing sustained growth inhibition in cells, xenografts, and syngeneic mouse TNBC models. Pharmacologic targeting of P-TEFb members in conjunction with MEK inhibition by trametinib is an effective strategy to durably inhibit epigenomic remodeling required for adaptive resistance.Significance: Widespread transcriptional adaptation to pharmacologic MEK inhibition was observed in TNBC patient tumors. In preclinical models, MEK inhibition induces dramatic genome-wide modulation of chromatin, in the form of de novo enhancer formation and enhancer remodeling. Pharmacologic targeting of P-TEFb complex members at enhancers is an effective strategy to durably inhibit such adaptation. Cancer Discov; 7(3); 302-21. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 235.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zawistowski JS, Bevill SM, Goulet DR, et al. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discov. 2017. PMID: 28108460. doi:10.1158/2159-8290.CD-16-0653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。